Pediatric Epilepsy
Zogenix, Inc. announced it has completed its rolling submission of a New Drug Application (NDA) to the FDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome.
Discover the latest about what's happening at CURE and in our community in the February 2019 CURE Update from Chief Scientific Officer, Laura Lubbers!
Pediatric Epilepsy
Lisuride, an anti-parkinson medicine with demonstrated anti-seizure effects, was able to stop epileptic activity in a model of convulsant Dravet syndrome zebrafish, researchers report.
SUDEP
New research confirms that if spreading depolarization of neurons engages the brainstem, the result is fatal.
This study presents the first evidence for the effectiveness of fenfluramine in reducing seizure incidence, severity, and seizure-induced respiratory arrest susceptibility in a mammalian SUDEP model.
According to this retrospective analysis, higher concentrations of lactate and total protein as well as blood-brain barrier dysfunction are often seen after epileptic seizures vs mild pleocytosis and Ig synthesis.
According to this population-based study, seizures in neonates seemed to play an important role in the development of epilepsy, intellectual disability and headache when covariates were observed to be equal.
A triple-blind trial found a benefit for supplementation with the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) among men and women with intractable seizures.
Regardless of seizure frequency, impaired awareness, cluster seizures, sleep-only seizures, and convulsive seizure were characteristics found to significantly influence injuries.
